Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Michel

Showing results (231-240 of 318) with videos related to

Pageof 32
Sort By:
British Journal of Haematology|October 11, 2011
Efficacy and safety of rituximab in common variable immunodeficiency-associated immune cytopenias: a retrospective multicentre study on 33 patientsDelphine Gobert, James B Bussel, Charlotte Cunningham-Rundles, et al.
The European Journal of Neuroscience|August 16, 2024
Impact of JQ1 treatment on seizures, hippocampal gene expression, and gliosis in a mouse model of temporal lobe epilepsyAileen Harnett, Justine Mathoux, Marc-Michel Wilson, et al.
American Journal of Hematology|December 11, 2019
Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopeniaAdrian C Newland, Blanca Sánchez-González, László Rejtő, et al.
Science Translational Medicine|April 15, 2021
Rituximab-resistant splenic memory B cells and newly engaged naive B cells fuel relapses in patients with immune thrombocytopeniaEtienne Crickx, Pascal Chappert, Aurélien Sokal, et al.
The Journal of Clinical Investigation|December 18, 2012
B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cellsMatthieu Mahévas, Pauline Patin, François Huetz, et al.
Alzheimer'S Research & Therapy|June 29, 2017
Long-term cognitive outcome of Alzheimer's disease and dementia with Lewy bodies: dual disease is worseFrédéric Blanc, Rachid Mahmoudi, Thérèse Jonveaux, et al.
Blood Advances|August 5, 2025
Safety and Efficacy of Daratumumab in Immune ThrombocytopeniaGalina Tsykunova, Pål Andre Holme, Hoa Thi Thyuet Tran, et al.
American Journal of Hematology|May 29, 2023
Sustained inhibition of complement C1s with sutimlimab over 2 years in patients with cold agglutinin diseaseAlexander Röth, Wilma Barcellini, Shirley D'Sa, et al.
Blood|June 10, 2022
Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trialAlexander Röth, Sigbjørn Berentsen, Wilma Barcellini, et al.
Journal of Autoimmunity|June 27, 2015
Emergence of long-lived autoreactive plasma cells in the spleen of primary warm auto-immune hemolytic anemia patients treated with rituximabMatthieu Mahévas, Marc Michel, Benoit Vingert, et al.
Pageof 32

Showing results (231-240 of 318) with videos related to

Sort By:
Pageof 32
British Journal of Haematology|October 11, 2011
Efficacy and safety of rituximab in common variable immunodeficiency-associated immune cytopenias: a retrospective multicentre study on 33 patientsDelphine Gobert, James B Bussel, Charlotte Cunningham-Rundles, et al.
The European Journal of Neuroscience|August 16, 2024
Impact of JQ1 treatment on seizures, hippocampal gene expression, and gliosis in a mouse model of temporal lobe epilepsyAileen Harnett, Justine Mathoux, Marc-Michel Wilson, et al.
American Journal of Hematology|December 11, 2019
Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopeniaAdrian C Newland, Blanca Sánchez-González, László Rejtő, et al.
Science Translational Medicine|April 15, 2021
Rituximab-resistant splenic memory B cells and newly engaged naive B cells fuel relapses in patients with immune thrombocytopeniaEtienne Crickx, Pascal Chappert, Aurélien Sokal, et al.
The Journal of Clinical Investigation|December 18, 2012
B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cellsMatthieu Mahévas, Pauline Patin, François Huetz, et al.
Alzheimer'S Research & Therapy|June 29, 2017
Long-term cognitive outcome of Alzheimer's disease and dementia with Lewy bodies: dual disease is worseFrédéric Blanc, Rachid Mahmoudi, Thérèse Jonveaux, et al.
Blood Advances|August 5, 2025
Safety and Efficacy of Daratumumab in Immune ThrombocytopeniaGalina Tsykunova, Pål Andre Holme, Hoa Thi Thyuet Tran, et al.
American Journal of Hematology|May 29, 2023
Sustained inhibition of complement C1s with sutimlimab over 2 years in patients with cold agglutinin diseaseAlexander Röth, Wilma Barcellini, Shirley D'Sa, et al.
Blood|June 10, 2022
Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trialAlexander Röth, Sigbjørn Berentsen, Wilma Barcellini, et al.
Journal of Autoimmunity|June 27, 2015
Emergence of long-lived autoreactive plasma cells in the spleen of primary warm auto-immune hemolytic anemia patients treated with rituximabMatthieu Mahévas, Marc Michel, Benoit Vingert, et al.
Pageof 32